Propanc Biopharma, Inc. (PPCB) shareholders
Close on Nov 12, 2026Market cap $12.16MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PPCB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 25,550 | 0.40% | $38.32K | New | 0.00% |
| Citadel Advisors LLC | 12,090 | 0.19% | $18.14K | New | 0.00% |
| Hrt Financial LP | 10,242 | 0.16% | $15.00K | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | 0.00% | $3 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.8% | 4 / 0 | 0 / 0 | 0M | 0M |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James Andrew Nathanielsz CEO/CFO, Director | Aug 17, 2021 | Award | +2,800,000 | – | – | 2,800,000 |
| James Andrew Nathanielsz CEO/CFO, Director | Aug 17, 2021 | Award | +5,928,000 | – | – | 5,928,004 |
| Julian Norman Kenyon Chief Scientific Officer, Director | Aug 17, 2021 | Award | +3,420,000 | – | – | 3,420,005 |
| Julian Norman Kenyon Director | Feb 4, 2015 | Other | +17,654,470 | – | – | 28,466,534 |
| James Andrew Nathanielsz CEO, CFO, Secretary, Treasurer, Director | Feb 4, 2015 | Other | +33,259,350 | – | – | 42,711,111 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Jul 5, 2013 | Sale | −55,000 | $0.09 | $4.95K | 9,701,761 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Jan 23, 2013 | Sale | −15,000 | $0.20 | $3.00K | 9,756,761 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Dec 13, 2012 | Sale | −5,500 | $0.20 | $1.10K | 9,771,761 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Sep 14, 2012 | Sale | −5,000 | $0.20 | $1.00K | 9,777,261 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Sep 4, 2012 | Sale | −250,000 | $0.20 | $50.00K | 9,782,261 |
| James Andrew Nathanielsz Chief Executive Officer, Director, 10% owner | Aug 23, 2012 | Buy | −250,000 | $0.20 | $50.00K | 9,782,261 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Propanc Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 219,986 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?